Trendlines marks 3 years since its IPO

We marked our third anniversary of trading on the Catalist Board of the Singapore Stock Exchange (SGX) on 26 November 2018.

For the occasion, we hosted an investor event at the SGX, featuring Chairman and CEO Steve Rhodes, Trendlines Incubators Israel CEO Nitza Kardish, and presentations by Trendlines Agtech portfolio companies AlgaHealth, AquiNovo and FruitSpec.

See our presentation “Three years of building value 2015-2018” (PDF) that Steve presented at the Singapore investor event.

3 Years by the Numbers

  • Established 28 portfolio companies
  • Reached a portfolio value of $102.5 million
  • Completed 3 exits
  • Signed ~9 collaboration agreements with multinationals, including B. Braun and Bayer
  • Established 9 partnerships (Trendlines Medical Singapore)

Portfolio Development & Value

Three years of building value -- presentation cover

See “Three years of building value 2015-2018” (PDF), the presentation Steve Rhodes gave at the Singapore investor event.

On the day of the IPO, 26 November 2015, we had invested in 60 start-ups. In the three years since, we invested in an additional 28 early-stage companies, made numerous follow-on investments, and continued to provide our characteristic intensive support to develop our portfolio and build value.

Total portfolio value increased 28% since the listing from US$80 million in November 2015 to US$102.5 million in November 2018. Total portfolio value grew by 56%* over the three-year period, with 71% growth, including exit proceeds.

Since 2015, we exited three companies, bringing our total number of exits to eight.


*Excluding Stimatix GI, the assets of which were acquired by B. Braun prior to 2015 (and the value of its projected royalty stream has not changed significantly during the period).

Strategic Partnerships

Partnering and collaborating is at the core of our business ethos and plays a vital role in giving our companies access to international market players.

Commenting on the growth of Trendlines’ partnership network, Chairman and CEO Steve Rhodes commented: “In November 2015, B. Braun became our strategic partner. This relationship has since grown substantially, with B. Braun investing not only in Trendlines and our Singapore incubator,  Trendlines Medical Singapore, but in three of our portfolio companies.”

Since the IPO, we have substantially widened our network of multinational partnerships to include companies such as Bayer CropScience, Cogentix, Johnson & Johnson, Nutreco, Neovia, and others.

Trendlines Chairman and CEO Steve Rhodes

Since our listing on the SGX, Trendlines has deepened its ties with the Singaporean business and technology community —

  • Establishing Trendlines Medical Singapore.
  • Collaborating with Singaporean organizations such as NHG, SGH, K2 Global, A*Star, Enterprise Singapore.
  • Winning the Securities Investors Association (Singapore) (SIAS) Most Improved Governance for a Company Trading on the SGX. Trendlines moved up into the top 10% of all SGX-traded companies on issues of transparency and governance.

Trendlines Chairman and CEO Todd Dollinger adds: “As Trendlines celebrates this anniversary, we reiterate our commitment to ‘improving the human condition’ by inventing, investing in, and incubating early-stage, breakthrough medical and agricultural technologies in Israel, Singapore, and beyond.”

We are proud of our achievements to date and look forward to continuing to build value for the Company.

Trendlines Chairman & CEO Todd Dollinger